Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 967

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 967
---
 beneficiaries or dependents of such Persons) has any present or future right to benefits and that is or was sponsored, maintained, or contributed to or required to be sponsored, maintained or
contributed to by the Company or any Subsidiary or (ii) under which the Company or its Subsidiaries has or could reasonably be expected to have any present or future liability (actual or contingent).

(r) “” (including the terms “,” “” and “”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise;

(s) “” means the financing event by Parent after the date hereof which results in net proceeds to Parent
in an amount no less than Thirty-Five Million Dollars ($35,000,000) and provided that, for purposes of this definition, “net proceeds” is equal to the gross proceeds of the offering minus the reasonable fees

A-55

and expenses related thereto, including fees and expenses owed to legal and accounting advisors and investment bankers;

(t) “” means, if and only if the Closing Adjusted Cash Consideration is less than Zero Dollars
($0), the Closing Adjusted Cash Consideration in absolute value;

(u) “” means, if the
Closing Net Working Capital results in a deficit (e.g., the Closing Net Working Capital is less than the Targeted Net Working Capital) and that deficit is greater than Twelve Million Dollars ($12,000,000), the difference between the Closing
Net Working Capital and Twelve Million Dollars ($12,000,000);

(v) “” means the
quotient of (i) the Company Delayed Share Consideration (ii) the Company Fully Diluted Common Stock, rounded down six (6) decimal places;

(w) “” means the exclusivity and right of first offer agreement between TuHURA Biosciences, Inc., a
Delaware corporation and the Company, dated as of July 3, 2024;

(x) “” means the Federal Acquisition Regulation
codified at Title 48 of the Code of Federal Regulations, and any other applicable agency supplements thereto including, without limitation, the Department of Defense FAR Supplement codified at Title 48 of the Code of Federal Regulations and the
Health and Human Services Acquisition Regulation codified at Title 48 of the Code of Federal Regulations;

(y) “” means all Laws (i) governing the safety, efficacy